Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Company Overview

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia. Through strategic collaborations with pharmaceutical partners and research institutes, the company enhances its R&D capabilities, optimizes clinical development pathways and positions its therapies for potential global commercialization.

Atea’s leadership team brings extensive experience in antiviral drug discovery, clinical development and regulatory strategy. Under their guidance, the company has advanced multiple development candidates from preclinical stages into human trials. Atea continues to expand its scientific platform through in-licensing opportunities and collaborative research, with a goal of delivering safe and effective antiviral treatments to improve patient outcomes and respond to evolving public health challenges.

Key Stats

• Today's Range: $4.78 to $5.04
• 50-Day Range: $4.10 to $5.65
• 52-Week Range: $2.78 to $6.45
• Volume: 415,177 shs
• Average Volume: 340,072 shs
• Market Capitalization: $398.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Atea Pharmaceuticals Stock Analysis - MarketRank™

Atea Pharmaceuticals scored higher than 15% of companies evaluated by MarketBeat, and ranked 779th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Atea Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Atea Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($1.93) to ($1.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atea Pharmaceuticals is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atea Pharmaceuticals is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atea Pharmaceuticals has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.27% of the float of Atea Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Atea Pharmaceuticals has a short interest ratio ("days to cover") of 28.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Atea Pharmaceuticals has recently decreased by 6.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atea Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Atea Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.60% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/04/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVIR
• CIK: 1593899
• Web: www.ateapharma.com
• Phone: 857-284-8891
• Fax: N/A
• Employees: 70
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($2.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$158.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.01%
• Return on Assets: -51.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.89
• Quick Ratio: 7.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.53 per share
• Price / Book: 1.41

Miscellaneous

• Outstanding Shares: 80,030,000
• Free Float: 62,741,000
• Market Cap: $398.55 million
• Optionable: Optionable
• Beta: 0.31